B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PI4K2A

MOLECULAR TARGET

phosphatidylinositol 4-kinase type 2 alpha

UniProt: Q9BTU6NCBI Gene: 553615 compounds

PI4K2A (phosphatidylinositol 4-kinase type 2 alpha) is targeted by 5 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PI4K2A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1piceatannol1.102
2Adenosine0.691
3Aurintricarboxylic Acid0.691
4Gemfibrozil0.691
5Iodoacetamide0.691

About PI4K2A as a Drug Target

PI4K2A (phosphatidylinositol 4-kinase type 2 alpha) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 5 compounds with documented PI4K2A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PI4K2A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.